EP3390634A4 - Zusammensetzungen und verfahren zur behandlung von augenkrankheiten - Google Patents
Zusammensetzungen und verfahren zur behandlung von augenkrankheiten Download PDFInfo
- Publication number
- EP3390634A4 EP3390634A4 EP16876610.3A EP16876610A EP3390634A4 EP 3390634 A4 EP3390634 A4 EP 3390634A4 EP 16876610 A EP16876610 A EP 16876610A EP 3390634 A4 EP3390634 A4 EP 3390634A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- treatment
- methods
- eye diseases
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267259P | 2015-12-14 | 2015-12-14 | |
US201662318958P | 2016-04-06 | 2016-04-06 | |
PCT/US2016/066691 WO2017106370A1 (en) | 2015-12-14 | 2016-12-14 | Compositions and methods for treatment of eye diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3390634A1 EP3390634A1 (de) | 2018-10-24 |
EP3390634A4 true EP3390634A4 (de) | 2019-08-14 |
Family
ID=59057531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16876610.3A Pending EP3390634A4 (de) | 2015-12-14 | 2016-12-14 | Zusammensetzungen und verfahren zur behandlung von augenkrankheiten |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3390634A4 (de) |
JP (2) | JP7036723B2 (de) |
CA (1) | CA3005128A1 (de) |
WO (1) | WO2017106370A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
JP6867945B2 (ja) | 2014-10-03 | 2021-05-12 | コールド スプリング ハーバー ラボラトリー | 核内遺伝子出力の標的とされた増強 |
WO2017060731A1 (en) | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
EP3933041B1 (de) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense-oligomere zur behandlung von autosomaldominierender geistiger behinderung |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
KR102619197B1 (ko) | 2017-01-23 | 2024-01-03 | 리제너론 파마슈티칼스 인코포레이티드 | Hsd17b13 변종 및 이것의 용도 |
AU2018250727A1 (en) | 2017-04-11 | 2019-10-31 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (HSD17B) family |
GB201706009D0 (en) * | 2017-04-13 | 2017-05-31 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of stargardt disease |
PL3673080T3 (pl) | 2017-08-25 | 2024-03-11 | Stoke Therapeutics, Inc. | Oligomery antysensowne do leczenia stanów i chorób |
EP3695012B1 (de) | 2017-10-11 | 2023-03-08 | Regeneron Pharmaceuticals, Inc. | Hemmung von hsd17b13 in der behandlung der lebererkrankung bei patienten, die die pnpla3-i148m-variation exprimieren |
KR20200070367A (ko) * | 2017-10-23 | 2020-06-17 | 스톡 테라퓨틱스, 인크. | 넌센스 매개 rna 분해 기반 병태 및 질환 치료를 위한 안티센스 올리고머 |
RU177889U1 (ru) * | 2017-11-30 | 2018-03-15 | Общество с ограниченной ответственностью "Вертикаль-М" (ООО "Вертикаль-М") | Дренаж для хирургического лечения глаукомы |
AU2019255708A1 (en) * | 2018-04-17 | 2020-11-26 | Ascidian Therapeutics, Inc. | Trans-splicing molecules |
WO2019241648A1 (en) * | 2018-06-14 | 2019-12-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing stmn2 expression |
CR20210179A (es) * | 2018-07-03 | 2022-05-23 | Hoffmann La Roche | OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058) |
US20220098595A1 (en) * | 2019-01-25 | 2022-03-31 | Nayan Therapeutics, Inc. | Nr2e3 expression reducing oligonucleotides, compositions containing the same, and methods of their use |
EP4017979A4 (de) * | 2019-08-19 | 2024-03-27 | Stoke Therapeutics, Inc. | Zusammensetzungen und verfahren zur modulation von splicing und proteinexpression |
KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
WO2023104693A1 (en) * | 2021-12-07 | 2023-06-15 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting actl6b |
WO2023160454A1 (zh) * | 2022-02-25 | 2023-08-31 | 北京中因科技有限公司 | 表达盒组合及其应用 |
WO2024105673A1 (en) * | 2022-11-17 | 2024-05-23 | Skip Therapeutics Ltd. | Compositions and methods for treating retinal diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015035091A1 (en) * | 2013-09-04 | 2015-03-12 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9222088B2 (en) * | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
EP3778618A1 (de) * | 2013-02-04 | 2021-02-17 | Ionis Pharmaceuticals, Inc. | Selektive antisense-verbindungen und verwendungen davon |
GB201410693D0 (en) * | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
JP6867945B2 (ja) * | 2014-10-03 | 2021-05-12 | コールド スプリング ハーバー ラボラトリー | 核内遺伝子出力の標的とされた増強 |
-
2016
- 2016-12-14 CA CA3005128A patent/CA3005128A1/en active Pending
- 2016-12-14 JP JP2018529249A patent/JP7036723B2/ja active Active
- 2016-12-14 EP EP16876610.3A patent/EP3390634A4/de active Pending
- 2016-12-14 WO PCT/US2016/066691 patent/WO2017106370A1/en active Application Filing
-
2022
- 2022-01-04 JP JP2022000109A patent/JP2022046724A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015035091A1 (en) * | 2013-09-04 | 2015-03-12 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
Non-Patent Citations (2)
Title |
---|
JANA KRALOVICOVA ET AL: "Optimal antisense target reducing INS intron 1 retention is adjacent to a parallel G quadruplex", NUCLEIC ACIDS RESEARCH, vol. 42, no. 12, 8 July 2014 (2014-07-08), pages 8161 - 8173, XP055211568, ISSN: 0305-1048, DOI: 10.1093/nar/gku507 * |
TAKEMASA SAKAGUCHI ET AL: "Optineurin with amyotrophic lateral sclerosis-related mutations abrogates inhibition of interferon regulatory factor-3 activation", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 505, no. 3, 15 October 2011 (2011-10-15), pages 279 - 281, XP028114208, ISSN: 0304-3940, [retrieved on 20111021], DOI: 10.1016/J.NEULET.2011.10.040 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017106370A1 (en) | 2017-06-22 |
JP2019500348A (ja) | 2019-01-10 |
JP2022046724A (ja) | 2022-03-23 |
CA3005128A1 (en) | 2017-06-22 |
EP3390634A1 (de) | 2018-10-24 |
JP7036723B2 (ja) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3390634A4 (de) | Zusammensetzungen und verfahren zur behandlung von augenkrankheiten | |
EP3177732A4 (de) | Zusammensetzungen und verfahren zur behandlung von augenerkrankungen und augenleiden | |
EP3389725A4 (de) | Zusammensetzungen und verfahren zur behandlung von erkrankungen des zentralen nervensystems | |
EP3261440A4 (de) | Verfahren und zusammensetzungen zur behandlung genetischer augenerkrankungen | |
EP3347469A4 (de) | Verfahren und zusammensetzungen zur behandlung von glaukom | |
EP3224278A4 (de) | Verfahren und zusammensetzungen zur behandlung von gefässerkrankungen des auges | |
EP3389672A4 (de) | Zusammensetzungen und verfahren zur behandlung von leberkrankheiten | |
EP3347368A4 (de) | Verbindungen und formulierungen zur behandlung von augenerkrankungen | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
EP3185876A4 (de) | Zusammensetzungen und verfahren zur behandlung neurologischer erkrankungen | |
EP3390666A4 (de) | Zusammensetzungen und verfahren zur behandlung von nierenerkrankungen | |
EP3240612A4 (de) | Verfahren zur behandlung von netzhauterkrankungen | |
EP3341392A4 (de) | Zusammensetzungen und verfahren zur schmerzbehandlung | |
EP3265096A4 (de) | Ophthalmische zusammensetzungen und verfahren zur verwendung davon | |
EP3139928A4 (de) | Anordrin-zusammensetzungen und verfahren zur behandlung von krankheiten | |
EP3131556A4 (de) | Verfahren und zusammensetzungen zur behandlung von copd-erkrankungen | |
EP3110446A4 (de) | Verfahren und zusammensetzungen zur behandlung von siglec-8-assoziierten krankheiten | |
EP3086809A4 (de) | Zusammensetzungen und verfahren zur behandlung von augenerkrankungen | |
EP3515444A4 (de) | Zusammensetzung zur behandlung von augenerkrankungen und verfahren zur verwendung und herstellung | |
EP3240577A4 (de) | Verfahren und zusammensetzungen zur behandlung von hirnerkrankungen | |
EP3253211A4 (de) | Zusammensetzungen und verfahren zur behandlung von ödemen | |
EP3340974A4 (de) | Verfahren zur behandlung von erkrankungen | |
EP3484526A4 (de) | Zusammensetzungen und verfahren zur behandlung von herzkrankheiten | |
EP3481958A4 (de) | Verfahren und zusammensetzungen zur behandlung von störungen und erkrankungen mit rdh12 | |
EP3713553A4 (de) | Zusammensetzungen und verfahren zur behandlung von augenkrankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180706 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: AZNAREZ, ISABEL Inventor name: NASH, HUW M. Inventor name: HALL, SAMUEL W. Inventor name: AZARIAN, SASSAN |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190711 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101ALI20190705BHEP Ipc: C12N 15/113 20100101AFI20190705BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1262958 Country of ref document: HK |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KRAINER,ADRIAN Inventor name: AZNAREZ, ISABEL Inventor name: AZARIAN, SASSAN Inventor name: NASH, HUW M. Inventor name: HALL, SAMUEL W. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200527 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230922 |